252 related articles for article (PubMed ID: 37686522)
1. The Impact of ETV6-NTRK3 Oncogenic Gene Fusions on Molecular and Signaling Pathway Alterations.
Kinnunen M; Liu X; Niemelä E; Öhman T; Gawriyski L; Salokas K; Keskitalo S; Varjosalo M
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686522
[TBL] [Abstract][Full Text] [Related]
2. A highly conserved NTRK3 C-terminal sequence in the ETV6-NTRK3 oncoprotein binds the phosphotyrosine binding domain of insulin receptor substrate-1: an essential interaction for transformation.
Lannon CL; Martin MJ; Tognon CE; Jin W; Kim SJ; Sorensen PH
J Biol Chem; 2004 Feb; 279(8):6225-34. PubMed ID: 14668342
[TBL] [Abstract][Full Text] [Related]
3. Mutation of the salt bridge-forming residues in the ETV6-SAM domain interface blocks ETV6-NTRK3-induced cellular transformation.
Cetinbas N; Huang-Hobbs H; Tognon C; Leprivier G; An J; McKinney S; Bowden M; Chow C; Gleave M; McIntosh LP; Sorensen PH
J Biol Chem; 2013 Sep; 288(39):27940-50. PubMed ID: 23798677
[TBL] [Abstract][Full Text] [Related]
4. Mutations in the SAM domain of the ETV6-NTRK3 chimeric tyrosine kinase block polymerization and transformation activity.
Tognon CE; Mackereth CD; Somasiri AM; McIntosh LP; Sorensen PH
Mol Cell Biol; 2004 Jun; 24(11):4636-50. PubMed ID: 15143160
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of targeted therapy resistance in a pediatric glioma driven by
Keddy C; Neff T; Huan J; Nickerson JP; Beach CZ; Akkari Y; Ji J; Moore S; Nazemi KJ; Corless CL; Beadling C; Woltjer R; Cho YJ; Wood MD; Davare MA
Cold Spring Harb Mol Case Stud; 2021 Oct; 7(5):. PubMed ID: 34429303
[TBL] [Abstract][Full Text] [Related]
6. The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation.
Tognon C; Garnett M; Kenward E; Kay R; Morrison K; Sorensen PH
Cancer Res; 2001 Dec; 61(24):8909-16. PubMed ID: 11751416
[TBL] [Abstract][Full Text] [Related]
7. ETV6-NTRK3: a chimeric protein tyrosine kinase with transformation activity in multiple cell lineages.
Lannon CL; Sorensen PH
Semin Cancer Biol; 2005 Jun; 15(3):215-23. PubMed ID: 15826836
[TBL] [Abstract][Full Text] [Related]
8. Pan-tropomyosin receptor kinase immunoreactivity, ETV6-NTRK3 fusion subtypes, and RET rearrangement in salivary secretory carcinoma.
Yamamoto H; Nozaki Y; Sugii A; Taguchi K; Hongo T; Jiromaru R; Sato M; Nakano T; Hashimoto K; Fujiwara M; Oda Y
Hum Pathol; 2021 Mar; 109():37-44. PubMed ID: 33301751
[TBL] [Abstract][Full Text] [Related]
9. Generating in vitro models of NTRK-fusion mesenchymal neoplasia as tools for investigating kinase oncogenic activation and response to targeted therapy.
Vanoli F; Herviou L; Tsuda Y; Sung P; Xie Z; Fishinevich E; Min SS; Mallen W; de Wardin HT; Zhang Y; Jasin M; Antonescu CR
Oncogenesis; 2023 Feb; 12(1):8. PubMed ID: 36801905
[TBL] [Abstract][Full Text] [Related]
10. Case Report: Identification of a novel
Yu QX; Zhao WJ; Wang HY; Zhang L; Qin L; Zhang L; Han JL
Front Oncol; 2023; 13():1123812. PubMed ID: 37188179
[No Abstract] [Full Text] [Related]
11. A new ETV6-NTRK3 cell line model reveals MALAT1 as a novel therapeutic target - a short report.
Chen S; Nagel S; Schneider B; Dai H; Geffers R; Kaufmann M; Meyer C; Pommerenke C; Thress KS; Li J; Quentmeier H; Drexler HG; MacLeod RAF
Cell Oncol (Dordr); 2018 Feb; 41(1):93-101. PubMed ID: 29119387
[TBL] [Abstract][Full Text] [Related]
12. Cellular transformation and activation of the phosphoinositide-3-kinase-Akt cascade by the ETV6-NTRK3 chimeric tyrosine kinase requires c-Src.
Jin W; Yun C; Hobbie A; Martin MJ; Sorensen PH; Kim SJ
Cancer Res; 2007 Apr; 67(7):3192-200. PubMed ID: 17409427
[TBL] [Abstract][Full Text] [Related]
13. Nefarious NTRK oncogenic fusions in pediatric sarcomas: Too many to Trk.
Aepala MR; Peiris MN; Jiang Z; Yang W; Meyer AN; Donoghue DJ
Cytokine Growth Factor Rev; 2022 Dec; 68():93-106. PubMed ID: 36153202
[TBL] [Abstract][Full Text] [Related]
14. Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101.
Nagasubramanian R; Wei J; Gordon P; Rastatter JC; Cox MC; Pappo A
Pediatr Blood Cancer; 2016 Aug; 63(8):1468-70. PubMed ID: 27093299
[TBL] [Abstract][Full Text] [Related]
15. Expanding the Molecular Spectrum of Secretory Carcinoma of Salivary Glands With a Novel VIM-RET Fusion.
Skálová A; Banečkova M; Thompson LDR; Ptáková N; Stevens TM; Brcic L; Hyrcza M; Michal M; Simpson RHW; Santana T; Michal M; Vaněček T; Leivo I
Am J Surg Pathol; 2020 Oct; 44(10):1295-1307. PubMed ID: 32675658
[TBL] [Abstract][Full Text] [Related]
16. Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion.
Mortensen L; Ordulu Z; Dagogo-Jack I; Bossuyt V; Winters L; Taghian A; Smith BL; Ellisen LW; Kiedrowski LA; Lennerz JK; Bardia A; Spring LM
Oncologist; 2021 Oct; 26(10):818-824. PubMed ID: 34176200
[TBL] [Abstract][Full Text] [Related]
17. GISTs with
Cao Z; Li J; Sun L; Xu Z; Ke Y; Shao B; Guo Y; Sun Y
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612101
[TBL] [Abstract][Full Text] [Related]
18. Characterization of an ETV6-NTRK3 rearrangement with unusual, but highly significant FISH signal pattern in a secretory carcinoma of the salivary gland: a case report.
Wagner F; Greim R; Krebs K; Luebben F; Dimmler A
Diagn Pathol; 2021 Aug; 16(1):73. PubMed ID: 34372873
[TBL] [Abstract][Full Text] [Related]
19. Congenital mesoblastic nephroma is characterised by kinase mutations including EGFR internal tandem duplications, the ETV6-NTRK3 fusion, and the rare KLHL7-BRAF fusion.
Zhao M; Yin M; Kuick CH; Chen H; Aw SJ; Merchant K; Ng EHQ; Gunaratne S; Loh AHP; Gu W; Tang H; Chang KTE
Histopathology; 2020 Oct; 77(4):611-621. PubMed ID: 32590884
[TBL] [Abstract][Full Text] [Related]
20. The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells.
Wai DH; Knezevich SR; Lucas T; Jansen B; Kay RJ; Sorensen PH
Oncogene; 2000 Feb; 19(7):906-15. PubMed ID: 10702799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
